– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – April 23, 2025 -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus fulvestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at

April 23, 2025 -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from the company’s ongoing Phase 1/1b clinical trial of ficerafusp alfa in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual

— Oral presentation Tuesday, June 3, 2025 in Chicago — April 23, 2025 -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Phase 1/2 interim readout data from its U.S. NXC-201 NEXICART-2 trial in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 2025 American Society of Clinical Oncology Annual Mee

April 23, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a strategic collaboration with Catalent, a global leader in advanced delivery technologies, clinical development, and manufacturing solutions for therapeutics. Under the agreement, Catalent will conduct formulation development and clinical manufacturing activities for Silexion's n

In April 2021, Swiss pharmaceutical giant Roche celebrated the approval of its novel anti-influenza drug, Baloxavir Marboxil, in China. As the world’s first single-dose oral influenza treatment, Baloxavir quickly captured industry attention with its disruptive convenience and rapid symptom relief. However, Roche’s victory was short-lived. Just three months later, CSPC Ouyi Pharmaceutical, a subsidiary of Chinese pharmaceutical powerhouse CSPC Pharmaceutical Group, filed an application to launch

In July 2024, Swiss pharmaceutical giant Roche filed a lawsuit in a California district court that thrust Stanford University professors Maximilian Diehn and Ash Alizadeh into the center of a major controversy. This commercial dispute over cancer liquid biopsy technology not only involves $70 million in startup funding and a multibillion-dollar diagnostics market, but also exposes deep-rooted tensions between academic entrepreneurship and corporate interests in the biopharmaceutical sector. At t

In the biopharmaceutical industry, a quiet war is unfolding—one that involves billions of dollars in market value, patent strategies, and regulatory frameworks. The patent dispute between Swiss pharmaceutical giant Roche and American biotech heavyweight Biogen over Tocilizumab has emerged as a focal point in the global competition surrounding biosimilars. This lawsuit not only concerns the commercial interests of the two companies but also reflects the deeper conflict between biologic patent pro

April 17, 2025 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). Dr. Michael Ament of Cherry Creek Neurology presented his study entitled, “Adjunctive Non-Invasive Vagus

April 21, 2025 -- Eascra Biotech announced today that they have been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $274,990 to conduct research and development (R&D) to advance drug delivery systems capable of effectively targeting solid tumors. Eascra’s JBNps (Janus base nanoparticles) are an entirely new type of delivery platform that mimics DNA. The platform delivers RNA therapeutics to hard-to-reach treatment sites like joint cartilage

April 23, 2025 -- Bluejay Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases, today announced it will present new preclinical data on the characterization of BJT-188, a liver-targeted fatty acid synthase (FASN) inhibitor being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), at the European Association for the Study of the Liver (EASL) Congress 2025